DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20211647

Study of the cost variation analysis of anti-epileptic drugs available in different brands in Indian pharmaceutical market

Hansraj Kumar, Uma Shankar Prasad Kesari, Rajiv Kumar

Abstract


Background: The aim of this study was to analyze the cost ratio and percentage cost variations in different brands of the commonly prescribed anti-epileptic drugs available in Indian pharmaceutical market.

Methods: The maximum and minimum price of each brand of the drug given in Indian rupees (INR) was noted by using CIMS January to April 2020 edition and drug today April to June 2020 volume  1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of one bottle in case of 100 ml syrup and 10 tablets/capsules was calculated in case of oral drugs and the cost of one 1 vial or ampoule was noted in case of injectable drugs. At last the cost ratio and percentage cost variation of various brands was compared.

Results: After calculation of cost ratio and percentage cost variation for each brand of anti-epileptic drug tablet clonazepam (2 mg) shows highest cost ratio and percentage cost variation as 10.41 and 941.66, carbamazepine (200 mg SR tablet) shows lowest cost ratio and percentage cost variation as 1.09 and 9.32.

Conclusions: Epilepsy is the most common neurological disorder and epileptic drugs are to be prescribed for prolonged period. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment. There is a wide difference in the cost of different brands of anti-epileptic drugs available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.


Keywords


Anti-epileptic drugs, Percentage cost variation, Cost ratio

Full Text:

PDF

References


Chang BS, Lowenstein DH. Epilepsy. New England J Med. 2003;349(13):1257-66.

Epilepsy Fact sheet. WHO. February 2016. Archived from the original on 11 March 2016. Retrieved 4 March 2016

Dan L, Fauci A, Kasper D, Hauser S, Jameson JL, Loscalzo J. 369 Seizures and Epilepsy. Harrison's principles of internal medicine 18th ed. New York, NY: McGraw-Hill; 2011: 3258.

Fisher R, van-Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-2.

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602.

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544.

Holmes, Thomas R. Browne, Gregory L. Handbook of epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2008: 7.

Wyllie. In: Cascino GD, Gidal BE, Goodkin HP, eds. Wyllie's treatment of epilepsy: principles and practice. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2010.

Newton CR, Garcia HH. Epilepsy in poor regions of the world. Lancet. 2012;380(9848):1193-201.

National Clinical Guideline Centre. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Nat Instit Heal Clinic Excell. 2012:21-8.

Wyllie E. In: Cascino GD, Gidal BE, Goodkin HP, eds. Wyllie's Treatment of epilepsy: principles and practice. Lippincott Williams and Wilkins; 2012: 187.

National Clinical Guideline Centre. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Nat Instit Heal Clinic Excell. 2012:57-83.

Sarah JN, Anthony GM, Jennifer W, Catrin TS. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochr Database Syst Rev. 2016;4.

Graham P, Matthew S, Alexandra R, Anthony GM. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochr Database Syst Rev. 2016;12:7124.

Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patients cost-sharing trends affects adherence and out comes: a literature review: PT. 2012;37(1):45-55.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, eds. A textbook of clinical pharmacy practice. 1st ed. Hyderabad: Orient Longman; 2004: 723.

Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51(1):13-6.

Drug Cost Control. Government of India, 2013. Available at: http://www.nppaindia.nic.in/DPCO2013.Pdf. Accessed on 17 February 2021.

Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.